EXTON, Pa., Nov. 11, 2016 /PRNewswire/ -- Absorption Systems, a global leader in the science of translational medicine, announces the issuance of a U.S. patent for its unique In Vitro Dissolution Absorption System (IDAS2™) technology, which enables the simultaneous evaluation of drug dissolution and absorption in various dosage forms, including tablets, capsules, and pre-formulations. It is noteworthy that all claims in the patent application were granted, including both the device itself and the method of use. Industry demand for IDAS2 is already high, owing to its innovative design and integrated predictive ability.
With IDAS2, pharmaceutical scientists can now rapidly evaluate two fundamental properties of a finished drug product (tablet, capsule, etc.) at the same time: the dissolution rate, which is determined by the formulation (excipients) in which the active pharmaceutical ingredient (API) is packaged, and the absorption rate of the dissolved drug substance across a human intestinal cell monolayer, which is an intrinsic property of the API. And IDAS2 allows for the assessment of many formulations at the same time.
The ability to rapidly screen pre-formulations as well as finished oral dosage forms for both dissolution and permeability, simultaneously in an in vitro format, will improve the reliability of pre-clinical formulation testing, leading to better decisions concerning formulations that will advance to clinical testing in humans. Enhancing the predictive power of the system is the fact that IDAS2 includes the same human intestinal cells that Absorption Systems uses to classify drug permeability according to the Biopharmaceutics Classification System (BCS).
Dr. Jibin Li, co-inventor on the patent with Dr. Ismael J. Hidalgo, commented that, "The patent for IDAS2 validates a lot of hard work over several years, from conception to prototype to finished product. It's very rewarding to see our efforts come to fruition in this way and to know that this technology will help get more effective and safer drugs to patients sooner."
Absorption Systems will be well represented and participating in multiple scientific sessions at the Annual Meeting and Exposition (Booth #1401) of the American Association of Pharmaceutical Scientists (AAPS) in Denver, CO from November 13-17.
About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. IDAS2, a novel in vitro test system for simultaneous screening of drug absorption and dissolution, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry standard for formulation assessment. Absorption Systems, with facilities near Philadelphia, PA, in San Diego, CA, and in Panama, serves customers throughout the world. For information on the company's comprehensive contract services, applied research programs, and proprietary test systems, please visit www.absorption.com.
SOURCE Absorption Systems